Advertisement

Der Gynäkologe

, Volume 39, Issue 6, pp 420–427 | Cite as

Ovarialkarzinom

Epidemiologie, Genetik und Prävention
  • D. ReinEmail author
  • N. Arnold
  • D. Niederacher
Zum Thema
  • 74 Downloads

Zusammenfassung

Unter dem Begriff Ovarialkarzinom wird eine heterogene Gruppe unterschiedlicher Tumoren subsumiert. Die pathogenetischen Mechanismen der Tumorgenese von Ovarialkarzinomen wurden trotz zahlreicher Untersuchungen bislang erst ansatzweise verstanden. Die vollständige Entschlüsselung des humanen Genoms und die Entwicklung der Gen-Chip-Technologie ermöglichte die genomweite Erstellung von Genexpressionsprofilen von Zellen und Geweben. Wichtige Anwendungen dieses Expression Profiling im Bereich onkologischer Fragestellungen sind die Identifikation bzw. Klassifizierung eines Tumor-Phänotyps aufgrund seines Expressionsprofils (Signatur), Krankheitsverläufe (prognostische Signaturen) und Ansprechen auf therapeutische Maßnahmen (prädiktive Signaturen) vorherzusagen und neue molekulare Targets für medikamentöse Therapien zu identifizieren. Die vorliegende Arbeit vermittelt einen Überblick über genetische und molekulargenetische Grundlagen des Ovarialkarzinoms und Ansätze zur Prävention der Erkrankung.

Schlüsselwörter

Epitheliale Ovarialkarzinome Genexpressionsprofile Diagnostische Marker Prävention 

Ovarian carcinoma

Epidemiology, genetics and prevention

Abstract

A number of heterogeneous tumors are combined under the term “malignant ovarian tumors”. Numerous studies have been performed to improve our knowledge of the morphology and biological behavior of these, however, the underlying mechanisms of tumorigenesis of ovarian cancer are still not fully understood. Novel molecular techniques, such as gene-chip technologies, allow new insights into the genetic basis of ovarian cancer. Expression profiling allows the identification and characterization of morphologically heterogeneous tumor types. Several candidate markers have been identified for the early detection and prediction of such tumors. In addition, novel targets that might have the potential to be exploited therapeutically have been identified. This review provides an overview on the genetic and molecular basis of the disease as well as options for the prevention of hereditary ovarian cancer.

Keywords

Epithelial ovarian cancer Gene expression profiling Diagnostic marker Prevention 

Notes

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Literatur

  1. 1.
    Bell DA, Scully RE (1994) Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 73: 1859–1864PubMedGoogle Scholar
  2. 2.
    Chan WY, Cheung K-K, Schorge JO et al. (2000) Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156: 409–417PubMedGoogle Scholar
  3. 3.
    Colgan TJ, Boerner SJ, Murphy J et al. (2002) Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85: 397–403CrossRefPubMedGoogle Scholar
  4. 4.
    Dietel M, Hauptmann S (2000) Serous tumors of low malignant potential of the ovary. Virchows Arch 436: 403–412CrossRefPubMedGoogle Scholar
  5. 5.
    Donninger H, Bonome T, Radonovich M et al. (2004) Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065–8077CrossRefPubMedGoogle Scholar
  6. 6.
    Einav U, Tabach Y, Getz G et al. (2005) Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 24: 6367–6375PubMedGoogle Scholar
  7. 7.
    Israeli O, Goldring-Aviram A, Rienstein S et al. (2005) In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 160: 35–42CrossRefPubMedGoogle Scholar
  8. 8.
    Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–1615CrossRefPubMedGoogle Scholar
  9. 9.
    Lancaster J, Dressman H, Whitaker R et al. (2004) Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51–59CrossRefPubMedGoogle Scholar
  10. 10.
    Lu KH, Garber JE, Cramer DW et al. (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18: 2728–2732PubMedGoogle Scholar
  11. 11.
    Lux MP, Bani MR, Fasching PA, Beckmann MW (2005) Prophylaktische Chirurgie des Mamma- und Ovarialkarzinoms. Chirurg 76: 1145–1154CrossRefPubMedGoogle Scholar
  12. 12.
    Marquez RT, Baggerly KA, Patterson AP et al. (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116–6126CrossRefPubMedGoogle Scholar
  13. 13.
    Mink P, Sherman M, Devesa S (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978–1998. Cancer 95: 2380–2389CrossRefPubMedGoogle Scholar
  14. 14.
    Modan B, Hartge P, Hirsh-Yechezkel et al. (2001) National Israel Ovarian Cancer Study group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345: 35–40CrossRefGoogle Scholar
  15. 15.
    Modesitt SC, Tortolero-Luna G, Robinson JB et al. (2002) Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 100: 788–795CrossRefPubMedGoogle Scholar
  16. 16.
    Piver MS, Barker TR, Jishi MF et al. (1993) Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 71: 582–588PubMedGoogle Scholar
  17. 17.
    Prat J, Ribe A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36: 861–870CrossRefPubMedGoogle Scholar
  18. 18.
    Ross JS, Yang F, Kallakury BV et al. (1999) HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 111: 311–316PubMedGoogle Scholar
  19. 19.
    Rebbeck TR, Lynch HAT, Neuhausen SL et al. (2002) The prevention and observation of surgical end points study group. Prophylactic surgery in patients with BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616–1622CrossRefPubMedGoogle Scholar
  20. 20.
    Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE (1996). Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7: 361–364PubMedGoogle Scholar
  21. 21.
    Seidman JD, Russell P, Kurman RJ (2002) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, Heidelberg Berlin New York Tokyo, S 791–904Google Scholar
  22. 22.
    Shih I-M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511–1518PubMedGoogle Scholar
  23. 23.
    Singer G, Kurman RJ, Chang HW et al. (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160: 1223–1228PubMedGoogle Scholar
  24. 24.
    Singer G, Oldt III R, Cohen Y et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484–486PubMedGoogle Scholar
  25. 25.
    Sommer A, Hilpert F, ArnoldN (2006) Gene expression profiling of epithelial ovarian cancer. Curr Genomics (im Druck)Google Scholar
  26. 26.
    Spentzos D, Levine D, Ramoni M et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700–4710CrossRefPubMedGoogle Scholar
  27. 27.
    Spentzos D, Levine DA, Kolia S et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911–7918CrossRefPubMedGoogle Scholar
  28. 28.
    Therasse P, Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205–216PubMedGoogle Scholar
  29. 29.
    Zhang L, Conejo-Garcia J, Katsaros D et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203–213CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Klinik für Gynäkologie und GeburtshilfeUniversitätsklinikum Schleswig-Holstein, Campus Kiel
  2. 2.UniversitätsfrauenklinikDüsseldorf

Personalised recommendations